We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01117077
Recruitment Status : Unknown
Verified May 2010 by Shanghai Jiao Tong University School of Medicine.
Recruitment status was:  Enrolling by invitation
First Posted : May 5, 2010
Last Update Posted : May 5, 2010
Information provided by:
Shanghai Jiao Tong University School of Medicine

Brief Summary:
Infection accounted for the first cause of death in patients after liver transplantation, and 2 / 3 of the cause of death was fungal infections. The investigators group early found that T cell subsets playing a role of inducing immune tolerance were significantly increased in vivo of liver transplantation patients with aspergillus infection, which may be a kind of Treg cells expressing IL-17. To explore the immune tolerance mechanism induced by the immune balance cells is important to liver transplantation patients for improving efficacy and reducing the mortality. Therefore, the investigators are going to get the blood sample and liver tissue of the liver transplantation patients before and after treatment of aspergillus infection, flow cytometry analysis of blood T cell subsets, Cytometric Bead Array to detect changes in blood cytokines, laser capture microdissection to obtain liver biopsies of inflammatory cells in portal area and further for analysis of T cell subsets and protein. And the investigators are also to investigate the characteristics of CCR6 + CD4 + FOXP3 + Treg cell clones secreting IL-17 and the capacity of which suppressing conventional T cell proliferation. This study may find new methods, such as certain types of T cell subsets or cytokines for the treatment of liver transplant patients, which not only to anti-rejection but also to reduce fungal infection.

Condition or disease
Liver Transplantation Aspergillus Interleukin-17 Treg Cell Immune Tolerance

Study Type : Observational
Actual Enrollment : 50 participants
Observational Model: Case Control
Time Perspective: Prospective
Study Start Date : May 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
liver transplantation patients with aspergillus infection or without aspergillus infection

Inclusion Criteria:

Liver transplantation patients

Exclusion Criteria:


Responsible Party: Shanghai First People's Hospital
ClinicalTrials.gov Identifier: NCT01117077     History of Changes
Other Study ID Numbers: 10ZR1423900
First Posted: May 5, 2010    Key Record Dates
Last Update Posted: May 5, 2010
Last Verified: May 2010

Keywords provided by Shanghai Jiao Tong University School of Medicine:
liver transplantation
aspergillus infection
Treg cell
immune tolerance